Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion
- PMID: 16497943
- DOI: 10.1373/clinchem.2005.058198
Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion
Abstract
Background: The heme precursors porphobilinogen (PBG) and 5-aminolevulinic acid (ALA) accumulate during overt crises of acute intermittent porphyria (AIP), and high excretion of these metabolites often continues in the asymptomatic phase.
Methods: We measured concentrations of PBG and ALA and investigated the correlation between these metabolites in plasma and urine in 10 asymptomatic AIP carriers with high excretion and in 5 healthy individuals. We quantified plasma concentrations with an HPLC-mass spectrometric method and urine concentrations with ion-exchange chromatography.
Results: The mean (SD) plasma concentrations of PBG and ALA in the AIP carriers were 3.1 (1.0) and 1.7 (0.7) micromol/L, respectively. The mean 8-h urinary excretion amounts of PBG and ALA in the AIP carriers were 102 (25) and 56 (18) micromol, respectively, whereas the corresponding values for healthy individuals were 2.9 (0.7) and 9.3 (1.2) micromol. The correlations between PBG and ALA values in plasma and urine of the AIP carriers were 0.678 and 0.856, respectively. The mean PBG/ALA ratio was approximately 2.0 in both plasma and urine for the AIP carriers and 0.3 in urine for the healthy individuals. The renal clearance rates for PBG and ALA were 71 (15) and 70 (13) mL/min, respectively.
Conclusions: The described HPLC-mass spectrometric method enabled characterization of variations in plasma PBG and ALA in AIP carriers during an 8-h period. The renal clearances were similar for both metabolites. This method could be used to monitor AIP patients during treatment.
Similar articles
-
Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.Clin Pharmacokinet. 2007;46(4):335-49. doi: 10.2165/00003088-200746040-00006. Clin Pharmacokinet. 2007. PMID: 17375984 Clinical Trial.
-
A LC-MS/MS method for the specific, sensitive, and simultaneous quantification of 5-aminolevulinic acid and porphobilinogen.J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Aug 15;879(24):2389-96. doi: 10.1016/j.jchromb.2011.06.034. Epub 2011 Jul 6. J Chromatogr B Analyt Technol Biomed Life Sci. 2011. PMID: 21783436 Free PMC article.
-
Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.Eur J Intern Med. 2009 Mar;20(2):201-7. doi: 10.1016/j.ejim.2008.06.012. Epub 2008 Aug 8. Eur J Intern Med. 2009. PMID: 19327613 Clinical Trial.
-
Understanding Carbohydrate Metabolism and Insulin Resistance in Acute Intermittent Porphyria.Int J Mol Sci. 2022 Dec 20;24(1):51. doi: 10.3390/ijms24010051. Int J Mol Sci. 2022. PMID: 36613492 Free PMC article. Review.
-
Molecular diagnostics of acute intermittent porphyria.Expert Rev Mol Diagn. 2004 Mar;4(2):243-9. doi: 10.1586/14737159.4.2.243. Expert Rev Mol Diagn. 2004. PMID: 14995910 Review.
Cited by
-
Normal reference ranges for urinary δ-aminolevulinic acid and porphobilinogen levels.JIMD Rep. 2020 Oct 1;57(1):85-93. doi: 10.1002/jmd2.12173. eCollection 2021 Jan. JIMD Rep. 2020. PMID: 33473344 Free PMC article.
-
Acute hepatic porphyrias: Recommendations for evaluation and long-term management.Hepatology. 2017 Oct;66(4):1314-1322. doi: 10.1002/hep.29313. Epub 2017 Sep 4. Hepatology. 2017. PMID: 28605040 Free PMC article. Review.
-
Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators.Int J Mol Sci. 2021 Jan 12;22(2):675. doi: 10.3390/ijms22020675. Int J Mol Sci. 2021. PMID: 33445488 Free PMC article. Review.
-
Acute Intermittent Porphyria: Current Perspectives And Case Presentation.Ther Clin Risk Manag. 2019 Dec 16;15:1443-1451. doi: 10.2147/TCRM.S180161. eCollection 2019. Ther Clin Risk Manag. 2019. PMID: 31908464 Free PMC article. Review.
-
Pharmacokinetic-pharmacodynamic model of urinary δ-aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria.CPT Pharmacometrics Syst Pharmacol. 2023 Jun;12(6):842-852. doi: 10.1002/psp4.12957. Epub 2023 Mar 23. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36883675 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous